MME and synovitis: Based on our findings, we propose a proof-of-concept viable cell-free CD10-based sEV alternative to MSC-based therapeutics in the treatment of inflammatory joint diseases, and perhaps OA phenotypes, where synovitis/IFP fibrosis and articular cartilage degradation are dominant.